Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by patience69on Jun 24, 2018 5:37pm
244 Views
Post# 28221253

AGM

AGMIt"s a shame how off topic we get here & how certain nameless individuals carry on but in fairness to the excellent effort by harpos I should add a little. Thank you harpos . I too was there & was nothing short of impressed. Im quite sure that from where you were  sitting harpos you may not have heard everything Dr Mandel especially said. He was sort of half in half out of the meeting in a doorway . I was close by. It is my opinion that they have ABSOLUTELY no intention to dilute this company any more than is necessary. He even said that since there are a large number of shares owned by himself & other insiders that is not a possibility. I really think that people should put that out of their minds. It is my opinion that they really feel they wont need the entire money & certainly not in a hurry. He & RW said that they intend to NEGOTIATE with the regulatory authorities ahead of time for some sort of potential of early ending of phase 2 with certain goals being met. Their confidence exudes. Dr Jewett defintely left the impression that he feels that with what he has seen so far (he was there through all patients) & the outcome in phase 1 he sees little reason that this will not be a success. I am an optomist by nature but truly left more upbeat than ever. Dr Mandel passes off any interest of a rollback so lets stop talking about it. I think they as much as know that such an action will not be necessary. Think about it with some grants???, good results the warrant money that makes total sense. I have been investing for 30 years & have never felt more comfortable that the team has their interests aligned with ours . The team is just that. Friendly personal banter afterward says a lot. 
I entered the meeting with one question to pose . I wanted to know about the status of Rutherrin . Somebody beat me to the question. Dr M feels that it will be a process but  fairly easy to convince of its safety as both individual chemicals  have now been proven safe & tolerable. 
As far as the answer to patient  5 & 6 data being released Dr M originally said  December but then did admit that he may be obligated to release sooner. Dr J spoke up with a little grin & said that it would be in his best interest to have the extra data available for  his sales pitch to other urologists to become involved in phase 2. He feels that this is a procedure that with some "babysitting" could be done in many centres effectively. That tells me the entire bladder cancer tx will remain in the hands of TLT. Awesome. Assuming that only a couple of mandatory treatments are necessary the case could be fairly easily made that TLT tx is way more cost effective. Not to mention when you see what some patients are forced to go through under the current standard of care. Its horrible. Lets not argue amonst ourselves but keep looking forward to our success.
Sorry this is a lttle long winded. I may add more as I think of it.
Bullboard Posts